| Name | Title | Contact Details |
|---|
DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders` groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.
Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.